Saltar a búsqueda.
 Dow Descenso0.10% Nasdaq Ascenso0.23%

Peregrine Pharmaceuticals, Inc. (PPHM)

1.73 0.04(2.37%) 17 de abr 4:00 p.m. EDT
Añadir a Portafolio
PerfilVer Perfil de:
Peregrine Pharmaceuticals, Inc.
14282 Franklin Avenue
Tustin, CA 92780
United States - Mapa
Teléfono: 714-508-6000
Fax: 714-838-5817
Sitio web:

Empleados a tiempo completo:182

Resumen empresarial (en inglés) 

Peregrine Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development of monoclonal antibodies focused on the treatment and diagnosis of cancer. The company’s lead product candidates in development include Bavituximab, a phosphatidylserine (PS) targeting agent that completed Phase IIb second-line non-small cell lung cancer trial for the treatment of solid tumors; and Cotara, a DNA/histone-targeting antibody that completed Phase II multicenter trial for the treatment of brain cancer. It is also conducting various other trials with bavituximab in combination with other therapies in multiple oncology indications as potential secondary indications for bavituximab; and an open-label single-center clinical trial under an exploratory investigational new drug application filed with the FDA for its lead imaging agent 124I-PGN650 for the imaging of multiple solid tumor types. In addition, the company, through its subsidiary, Avid Bioservices, Inc., provides various contract biomanufacturing services that support the development and current good manufacturing practices (cGMP) production of clinical and commercial monoclonal antibodies, and recombinant proteins and enzymes, including cell culture development, process development, and testing of biologics for biopharmaceutical and biotechnology companies under cGMP. It has license, research, and development agreements with the University of Texas Southwestern Medical Center; Genentech, Inc.; Avanir Pharmaceuticals, Inc.; Lonza Biologics; Affitech A/S; UTSWMC; and Merck KGaA. The company was founded in 1981 and is based in Tustin, California.

Estadísticas clave

Sitios web de la empresa 
Home Page
Búsqueda en Yahoo! de:
Más sobre Peregrine Pharmaceuticals, Inc.

Mr. Steven W. King , 50
Chief Exec. Officer, Pres, Director, Chief Exec. Officer of Avid Bioservices Inc and Pres of Avid Bioservices Inc
Mr. Paul J. Lytle CPA, 46
Chief Financial Officer, Principal Accounting Officer, Corp. Sec., Chief Financial Officer of Avid Bioservices Inc and Corp. Sec. of Avid Bioservices Inc
Mr. Mark R. Ziebell J.D., 50
VP, Gen. Counsel and Corp. Sec.
Dr. Shelley P. M. Fussey Ph.D., 48
VP of Intellectual Property
Mr. Joseph S. Shan M.P.H., 41
VP of Clinical & Regulatory Affairs
Las cantidades son con fecha de dic 31, 2013 y los valores de compensación son los del último año fiscal que finalizó en dicha fecha. Por sueldo se entiende salario, bonificaciones, etc. Ejercido representa el valor de las opciones ejercido durante el año fiscal.
Divisa en USD.
Ver ejecutivos